<DOC>
	<DOCNO>NCT00515463</DOCNO>
	<brief_summary>The purpose study compare immunogenicity profile denosumab pre-filled syringe ( PFS ) vial 6 month postmenopausal woman low bone mineral density ( BMD ) .</brief_summary>
	<brief_title>A Multi-Center , Randomized , Open-Label Study Assess Immunogenicity Safety Denosumab Pre-filled Syringe Compared Vial Subjects With Low Bone Mineral Density</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Patients successfully complete 20050141 study ( NCT00330460 ) : Must receive SC investigational product administration 20050141 Must take proscribed therapy 20050141 Subjects alendronate denosumab treatment group allow Provide sign informed consent studyspecific procedure conduct Any disorder , opinion investigator , may compromise ability patient give write informed consent and/or comply study procedure include : Any physical psychiatric disorder Or evidence alcohol substance abuse last 12 month Any clinical evidence , medical judgement investigator , follow medical condition : Impaired thyroid function ( subsequent treatment ) Impaired hepatic function Impaired renal function Rheumatoid Arthritis , Paget 's disease , Cushing 's disease , hyperprolactinemia , cirrhosis liver Known test positive human immunodeficiency virus , hepatitis C virus , hepatitis B surface antigen Any metabolic bone disease , eg , osteomalacia osteogenesis imperfecta , may interfere interpretation finding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Osteopenia</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>AMG 162</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Pre-filled syringe</keyword>
</DOC>